Perilous Reversal Stock: Insys Therapeutics (INSY)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Insys Therapeutics ( INSY) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Insys Therapeutics as such a stock due to the following factors:

  • INSY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $23.7 million.
  • INSY has traded 180,379 shares today.
  • INSY is down 3.2% today.
  • INSY was up 5.8% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in INSY with the Ticky from Trade-Ideas. See the FREE profile for INSY NOW at Trade-Ideas

More details on INSY:

Insys Therapeutics, Inc., a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. INSY has a PE ratio of 21.1. Currently there are 2 analysts that rate Insys Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Insys Therapeutics has been 543,600 shares per day over the past 30 days. Insys has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 42.5% year-to-date as of the close of trading on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

Alder Shares Plummet Almost 25% Despite Positive Data; Aralez Pops on Patent Victory: Biotech Movers

Opioid Marketing Under Bipartisan Investigation

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Launch of Cannabis ETF May Not Be Best Option for Investors